LYCOS RETRIEVER 
Merck: Alnylam Pharmaceuticals
built 623 days ago
Alnylam and Merck have entered into two separate, but complementary, strategic collaborations. The program to develop an RNAi therapeutic for spinal cord injury falls within the first of these collaborations, initiated in September 2003. The goals of this collaboration are to advance RNAi technology and to apply this technology to develop RNAi therapeutics that selectively target human diseases. For therapeutics development, Merck proposes potential targets to Alnylam, and if Alnylam develops a candidate RNAi therapeutic against a "Merck target" to a defined point in preclinical development, Merck may then opt to co-develop and co-promote this RNAi therapeutic with Alnylam. If Merck exercises this option it will pay Alnylam an option fee, reimburse Alnylam for fifty percent of its expenses previously incurred on the candidate RNAi therapeutic, and co-fund development from that point.
Source:
According to the complaint outlining the Commission’s charges, Medco negotiates with pharmaceutical manufacturers, including Merck, concerning placement of drugs on the Medco formulary. Medco ... negotiates rebates, discounts, and prices that pharmacy benefit plans managed by Medco pay for pharmaceutical products. Medco, the FTC charged, thereby influences the prices of pharmaceutical products and the availability of such products under the Medco pharmacy benefit plans.
Source:
The second collaboration between Alnylam and Merck, initiated in June 2004, is focused on age-related macular degeneration (AMD) and other ocular diseases caused by abnormal growth or leakage of small blood vessels in the eye. This collaboration includes Alnylam's most advanced program, to develop a Direct RNAi(TM) Therapeutic targeting vascular endothelial growth factor (VEGF) for the treatment of the "wet" form of AMD.
Source:
Jess joined Merck in March 2007 originally in a customer service roll. Jess services the eastern suburbs of Melbourne & Victoria. She has a Bachelor of Technology in Forensic and Analytical Chemistry as well as laboratory experience in the pharmaceutical industry and laboratory based water testing experience.
Source:
MORE ABOUT
Alnylam Pharmaceuticals